Hormone panel testing
Hormone panel testing measures sex hormones, thyroid function, and adrenal markers using clinically established assays long used in endocrinology, making the test method itself well-evidenced. Within the Atlas, the category has organized into two distinct commercial segments: women's menopause-focused platforms and men's testosterone optimization platforms, plus dedicated testing-only services. Evidence tier: well-evidenced.
What it is
Hormone panel testing measures circulating levels of sex hormones (estrogen, progesterone, testosterone), thyroid hormones and antibodies, and adrenal markers such as cortisol and DHEA, through blood, saliva, or urine sampling, to assess endocrine function and identify imbalances driving symptoms such as fatigue, mood disruption, weight change, or reproductive and sexual health complaints. The underlying laboratory assays are clinically established and have been used in endocrinology and primary care for decades, making the diagnostic method itself well-evidenced even where interpretation and treatment thresholds vary across specialties. In the longevity economy, hormone panel testing has organized into two distinct commercial segments with largely separate provider bases: women's hormone and menopause-focused platforms addressing perimenopause, menopause, and reproductive hormone health, and men's hormone optimization platforms centered on testosterone and andropause-related decline, alongside a smaller set of dedicated testing-only services. This bifurcation reflects differentiated demand rather than any difference in the underlying test, and most providers layer counseling, hormone therapy, or supplementation on top of the panel as their primary commercial offering.
Who it is for
Hormone panel testing serves adults experiencing symptoms plausibly linked to hormonal change, women navigating perimenopause and menopause, men experiencing age-related testosterone decline, and patients with suspected thyroid or adrenal dysfunction. It is also used proactively by longevity-engaged consumers seeking a baseline endocrine profile before considering hormone optimization or replacement therapy.
What to expect
Hormone panel testing is typically delivered as a blood draw, sometimes supplemented with saliva or urine collection for certain adrenal or metabolite markers, performed at a clinic, lab partner, or via at-home kit, with results reviewed in a follow-up consultation that interprets levels against symptoms and sets a treatment plan if indicated. Panels vary considerably by provider and target population: women's platforms typically emphasize estrogen, progesterone, and thyroid markers tracked across a cycle or menopause transition, while men's platforms emphasize total and free testosterone alongside markers used to monitor therapy safety. Retesting every three to six months is common once any hormone therapy begins, to titrate dosing.
History and background
Clinical hormone assays developed through twentieth-century endocrinology and became routine diagnostic tools well before the longevity industry existed, with thyroid and reproductive hormone testing long established in mainstream primary care and specialist practice. The commercial reorganization of hormone testing into consumer-facing longevity products accelerated through the 2010s and 2020s alongside growing public attention to menopause care, a historically underserved area of medicine, and to testosterone replacement therapy marketed to aging men. This period saw the emergence of dedicated women's menopause platforms and men's hormone optimization clinics as distinct commercial categories, each building a testing-plus-treatment model around panels that endocrinology had already validated diagnostically.
Worth knowing
The Atlas data shows hormone panel testing splitting cleanly along a gender line at the business-model level: women's hormone and menopause platforms (Stella, Elektra Health, Health & Her, Nabta Health, Maven Clinic, Evela) and men's hormone optimization platforms (Cenegenics, Hone Health) rarely overlap in provider or marketing strategy, despite testing overlapping categories of hormones, alongside dedicated testing-only services (Hormona, Hertility Health). Menopause care in particular has been characterized by clinicians and researchers as historically underfunded relative to its prevalence and symptom burden, a gap the women's hormone platform segment has grown explicitly to address. The bifurcation is a clear example of how a single, clinically uncontroversial diagnostic can support two structurally separate commercial markets.
Offered across the Atlas 12
Related modalities